Pharma industry is witnessing a trend of externalizing various functions to smaller biotechs and specialized organizations, such as research, clinical trials, and commercial analysis, driven by the need for efficiency. However, this externalization might lead to trade-offs and redundancy. Concerns exist regarding potential lack of incentives for companies to invest in developing new drugs, leading to a focus on marketing existing drugs and prolonging patent life. The focus on accounting over innovation poses a danger of impeding breakthroughs, emphasizing the importance of prioritizing R&D and giving scientists sufficient time to work on groundbreaking ideas for meaningful products.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode